FDA Oncology Announcements

Anti-EGFR × Other × Clear all

6 Announcements

FDA approves new dosing regimen for cetuximab

Drug: Erbitux (cetuximab) · Anti-EGFR antibody

Necitumumab

Drugs: PORTRAZZA (necitumumab) · Anti-EGFR antibody, gemcitabine · Pyrimidine analog, cisplatin · Platinum agent

Cetuximab in Combination with Folfiri / Therascreen

Drug: Erbitux (cetuximab) · Anti-EGFR antibody

Cetuximab (Erbitux)

Drug: Erbitux (cetuximab) · Anti-EGFR antibody

FDA Approves Cetuximab (Erbitux) and Panitumumab (Vectibix)

Drug: Vectibix Amgen (panitumumab) · Anti-EGFR antibody

Erbitux (ceuximab) Approved for Use in Combination with Radiation Therapy

Drug: Erbitux (cetuximab) · Anti-EGFR antibody